Skip to main content

Table 7 Lesion-based quantification parameters in T1 and T2

From: [68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study

Parameter Prostatic lesions T1 [mean; CI] Prostatic lesions T2 [mean; CI] p Lymphonodal lesions T1 [mean; CI] Lymphonodal lesions T2 [mean; CI] p Bone lesions T1 [mean; CI] Bone lesions T2 [mean; CI] p All lesions T1 [mean; CI] All lesions T2 [mean; CI] p
Score 2.33; 2.06–2.60 1.50; 1.07–1.93 0.001 2.00; 1.82–2.18 0.61; 0.35–0.86  < 0.001 1.52; 1.26–1.78 0.48; 0.22–0.74  < 0.001 1.94; 1.81–2.08 0.77;0.58–0.96  < 0.001
SUVmax 29.13; 20.11–38.15 14.67; 9.02–20.32 0.002 20.65; 15.50–25.81 8.17; 2.79–13.55  < 0.001 12.84; 8.27–17.41 3.48; 1.30–5.65  < 0.001 20.44; 16.86–24.02 8.35; 5.24–11.46  < 0.001
SUVmean 17.44; 11.99–22.89 8.63; 5.36–11.90 0.003 13.48; 10.09–16.86 5.10; 1.80–8.41  < 0.001 8.36; 5.37–11.36 2.20; 0.80–3.61  < 0.001 12.99; 10.72–15.26 5.11; 3.22–7.00  < 0.001
PSMA-TV [ml] 11.82; 8.13–15.51 3.32; 1.52–5.13  < 0.001 2.99; 1.39–4.60 0.23; 0.08–0.39  < 0.001 1.88; 1.24–2.52 0.98; 0.23–1.75 0.013 4.64; 3.29–5.98 1.12; 0.63 -1.60  < 0.001
TL-PSMA [ml] 253.16; 104.63–401.70 33.95; 9.68–58.22  < 0.001 41.62; 19.70–63.53 4.62; 0–10.48  < 0.001 21.03; 4.49–34.57 6.33; 0–13.65  < 0.001 82.72; 45.49–119.94 11.53; 4.99–18.07  < 0.001